•

🏦 Dalio's bond alarm: Ray Dalio says corporate cash flow is deteriorating as yields climb. The question is how much cushion is actually left. We measured it.

•

💊 Humana's 11.7% jump: Humana ($​HUM) rose 11.7% on a Medicare Stars ruling. The obvious question is why one rating decision does more for a stock than a full earnings beat. We explain.

•

🥊 Accenture, bull vs. bear: Jordan Bittencourt sees AI turning into a tailwind. Jess Langley thinks today's gap-up has already swallowed the upside. We let them fight it out.

•

📉 Spreads tell first: Dalio said the repricing has already pushed credit spreads wider. He stopped short of calling for an earnings decline or a near-term correction.

•

Yield arithmetic: The 10-year Treasury note hit its highest level since April 2002 this week before easing to 5.229% on Thursday. The 30-year sits at 5.602%, just off a 24-year high.

•

🏦 Two bidders, one pot: He expects the sell-off to run further as governments fund deficits and companies borrow for emerging technologies. Thursday's $​22bn 30-year reopening is that competition in public.

•

Cash-flow x-ray: Dalio expects free cash flow to deteriorate while headline earnings keep improving. Meaning: earnings are the showroom, and he thinks the fuel gauge is pointing the other way.

•

🥇 Dalio's own hedge: In August he advised cutting long-duration bond exposure and holding 10% to 15% of a portfolio in gold, alongside a smaller Bitcoin position. That tells you how he ranks the risk.

•

Where it bites first: The longest-duration equity stories should feel it soonest. Thursday's split, the Nasdaq down 1.25% against a Dow up 0.10%, looks like the opening page.

•

Our take: Investors have been paid for years to ignore the bond desk, and that payment is shrinking in real time. With the long end above 5% and corporate cash generation thinning, what premium are you actually being offered to own the equity?

•

The valuation case: Accenture, a global professional services leader in tech and operations, is delivering 6.5% annual revenue growth while holding a 15.4% operating margin - a combination that typically commands a durable multiple, and the Q4 results confirm AI is expanding project scope and pulling larger transformational mandates onto $​ACN's books.

•

The catalyst that changes the math: The market spent months assigning $​ACN a discount for AI exposure, and that discount has now dissolved on contact with actual results - clients are spending more on AI-led transformation, project volumes are rising, and the earnings base the market was discounting was structurally too conservative.

•

The risk I'd watch: A broad tech pullback - the Nasdaq is already down 1.25% today - could drag $​ACN lower regardless of fundamentals, so position sizing matters here more than the precise entry price itself.

•

The valuation trap: Jordan will point to 9.6x EV/EBITDA and call $​ACN cheap. But that multiple was struck before today's surge repriced the stock. The multiple you can actually buy this morning is richer than the one the bull case quotes, and at a 15.3x trailing P/E you are paying a premium-services price for a growth story the market has already absorbed in a single session.

•

The catalyst is spent: The Q4 AI tailwind narrative is real. It is also public, priced and crowded the moment a gap-up this size clears the tape. Chasing a catalyst after it has paid out its return in one move is usually how you end up holding the stock that institutions are rebalancing into, on a day the Dow managed 0.10%.

•

The FCF comfort is a ceiling: A 9.1% free cash flow yield sounds like a margin of safety, until the macro mood shifts and it compresses. Net leverage sits at exactly 0.0x, so there is no balance-sheet lever left to pull for a re-rating. Everything from here rests on growth multiples holding, which is precisely what the broader market is arguing about right now.